Loading...
Loading...
Jefferies' Jeffrey Holford raised five pharmaceuticals following key news on each company's products:
- Abbott ABT increased the price target to $45.00 after Abbot reported positive results from Type-1 Diabetes study. The study showed that Abbott system's significantly reduced Hypoglycemia.
- Bristol-Myers Squibb Company BMY raised the price objective to $78.00 after the company announced new data demonstrating continued research expansion and Immuno-Oncology Advancements across multiple blood cancers. Additionally, Bristo-Myers Squibb announced new data on Opdivo which indicated benefit in heavily pre-treated classical Hodgkin Lymphoma Patients in Phase 2.
- Johnson and Johnson JNJ price target raised to $109.00 after it announced EPREX demonstrated effectiveness as treatment for Anaemia in patients with low or intermediate-1 risk of Myelodysplastic syndromes at EHA Saturday.
- Pfizer PFE's price target rose to $42.00 after the company announced two pivotal phase 3 studies for Ertuglifozin Met Primary Endpoints, showing significant A1C reductions in patients with Type 2 Diabetes at the American Diabetes Association's 76th scientific sessions Sunday.
- Zoetis ZTS increased the price objective to $58.00 after Zoetis shares rose considerably over the last three months.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in